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Post-Transcriptional Regulation of Melanin
Biosynthetic Enzymes by cAMP and Resveratrol
in Human Melanocytes
Richard A. Newton1, Anthony L. Cook1, Donald W. Roberts1,2, J. Helen Leonard2 and Richard A. Sturm1
Upregulation of microphthalmia-associated transcription factor (MITF) expression has been proposed to
mediate melanogenesis stimulated by cAMP, whereas downregulation of MITF has been suggested to underlie
the depigmentary effects of resveratrol, a promising chemotherapeutic found in red wine. We have assessed the
contribution of MITF to pigmentation regulation by treating primary cultures of normal human melanocytes
with the adenylate cyclase activator forskolin and/or resveratrol, then quantifying mRNA and protein levels for
MITF, tyrosinase, tyrosinase-related protein-1, and dopachrome tautomerase (DCT). The inhibition of tyrosinase
activity by resveratrol was not due to alterations in MITF, but instead was explained by both direct tyrosinase
inhibition and a post-transcriptional effect that reduced the amount of fully processed tyrosinase. Glycosidase
digestion revealed that the basis for the tyrosinase decrease was the retention of an immature form in the ER
and subsequent loss of the mature, Golgi-processed enzyme. Elevation of intracellular cAMP by forskolin
markedly increased protein levels for MITF, tyrosinase and DCT, however there was no concomitant increase in
tyrosinase or DCT mRNA. This indicated that elevated levels of MITF were not sufficient to promote
transcription of these melanogenic genes and that the increase in their protein abundance appeared to be
predominantly mediated through post-transcriptional processing events.
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INTRODUCTION
Melanin synthesis (melanogenesis) is stimulated in human
melanocytes by an increase in the intracellular cAMP
concentration, which can be facilitated by activation of the
melanocortin-1 receptor or following the addition of exo-
genous cAMP elevating agents such as forskolin (Busca and
Ballotti, 2000). Central to this upregulation is increased
activity of tyrosinase, the rate-limiting enzyme for melano-
genesis. The molecular basis for this elevated activity has
been attributed to enhanced transcription of the tyrosinase
gene mediated via the binding of microphthalmia-associated
transcription factor (MITF) to promoter E-box motifs (Yasu-
moto et al., 1997; Bertolotto et al., 1998a). MITF has also
been shown to bind and transactivate promoter constructs for
the tyrosinase-related proteins (TYRPs), TYRP1 and dopa-
chrome tautomerase (DCT) (Aksan and Goding, 1998;
Bertolotto et al., 1998b). The expression of these two
enzymes is important for later steps in the synthesis of
eumelanin pigments. The transcription of MITF itself is
enhanced by the activation of a cAMP response element
contained within its promoter to provide a mechanism by
which cAMP can stimulate melanogenic enzyme expression
(Bertolotto et al., 1998a). This cascade therefore affords a
simplified scheme that has contributed to MITF being
considered a master regulator of human pigmentation.
Although MITF-mediated transcriptional activation of
pigmentation genes is essential for the control of melanocyte
cellular differentiation (Vance and Goding, 2004), the
upregulation of endogenous tyrosinase, TYRP1, and DCT
gene expression in mature melanocytes does not seem to be
satisfactorily explained by a simple direct transcriptional
control mechanism. For example, a-MSH-elicited cAMP
elevation in human melanocytes can increase protein levels
for the three melanogenic enzymes without any accompany-
ing change in mRNA levels, suggesting mediation via post-
transcriptional events (Abdel-Malek et al., 1995). Support for
the concept that as yet unidentified mechanisms underlie the
upregulation of tyrosinase elicited by activation of the cAMP
pathway was provided by a more recent study utilizing
adenovirus encoding wild-type MITF (Gaggioli et al., 2003).
Infection of human melanocytes with the recombinant virus
showed that the resultant elevation of MITF levels did not
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increase expression of endogenous melanogenic enzymes.
However, this same study also provided evidence that MITF
expression does still have a crucial involvement in the
regulation of human melanocyte pigmentation by demons-
trating an inhibitory effect of MITF-dominant-negative re-
combinant adenovirus on endogenous levels of tyrosinase
and TYRP1 proteins (Gaggioli et al., 2003).
A role for MITF levels in determining the extent of
melanocyte pigmentation is also provided by studies utilizing
a variety of depigmenting agents that have demonstrated
preceding reductions in MITF expression (Jimenez-Cervantes
et al., 2001; Kim et al., 2002a, 2004, 2006; Choi et al., 2005).
Resveratrol (3,5,40-trihydroxy-trans-stilbene), a polyphenol
found in red wine, has been proposed to represent another
such agent because it has been shown to both decrease skin
pigmentation and inhibit MITF promoter activity (Lin et al.,
2002). Interest in this compound has shown a marked renewal
in recent years, being initially triggered by its identification as a
chemotherapeutic agent for skin cancer (Jang et al., 1997) and
subsequently from its protective effects against heart disease
and ability to extend lifespans of lower organisms (reviewed in
Baur and Sinclair, 2006). We have examined the depigmenta-
tion effects of resveratrol and assessed whether MITF modula-
tion is an essential step in the negative regulation of
melanogenesis by this agent. In addition, we have investigated
the contribution of elevated MITF expression to the cAMP-
mediated upregulation of melanogenic enzymes in primary
human melanocytes. This has led to the identification of the
important role of post-transcriptional regulation of tyrosinase
in governing melanin pigment synthesis.
RESULTS
Resveratrol elicits a time-dependent decrease in tyrosinase
activity in human melanocytes that is unaffected by co-
treatment with forskolin
To evaluate the ability of resveratrol to decrease melanin
synthesis we assayed the tyrosinase activity of melanocytes,
both in situ (Figure 1a) and from extracts of treated cultures
(Figure 1b, d). Tyrosinase activity was measured because it is
known to closely correlate with melanin content of cultured
human melanocytes (Halaban et al., 1983; Wakamatsu et al.,
2006) and provides a more sensitive indicator of changes in
melanin synthesis than determination of total melanin levels.
Treatment of normal human melanocytes (NHM) with
resveratrol (20 mg/ml) for 24 hours profoundly decreased
in situ tyrosinase activity without affecting cell number
(Figure 1a). Although concentrations lower than 20 mg/ml
resulted in less inhibition of tyrosinase activity in NHM, a
significant decrease in activity was still apparent using only
0.25 mg/ml of resveratrol (data not shown) demonstrating the
potency and dose dependency of the effect. The resveratrol-
mediated decrease in tyrosinase activity, quantitated by both
3,4-dihydroxyphenylalanine (DOPA) oxidation and tritium
release from [3H]-tyrosine, was strongly time-dependent,
requiring 18–24 hours for the maximal 80% inhibition
(Figure 1b). This indicated that an indirect modulation of
cellular processes were involved in the profound reduction in
tyrosinase activity. There was also a smaller decrease in
tyrosinase activity of approximately 25% evident in lysates
within 30 minutes of adding resveratrol to melanocyte
cultures (Figure 1b), which indicated a possible direct
inhibitory effect of resveratrol. Direct inhibition of tyrosinase
by resveratrol was anticipated by virtue of its polyphenol
structure and was assessed in vitro by adding resveratrol
directly to untreated cell lysates and then measuring
tyrosinase activity (Figure 1c). DOPA oxidation activity was
decreased by 15% when resveratrol was added to melano-
cyte lysates at 20 mg/ml (88 mM), a finding in accordance with
an in vitro study of the effects of resveratrol added to a
preparation of murine tyrosinase where the IC50 for resver-
atrol-mediated inhibition of tyrosine oxidation was in excess
of 100mM (Kim et al., 2002b). However, we also found that
the in vitro effect of resveratrol on tyrosinase activity was
considerably more potent when determined under the
conditions of the tritium release assay resulting in a 75%
decrease in activity (Figure 1c) with an apparent IC50 of
approximately 2 mM (data not shown). This apparent dis-
cordance between the two tyrosinase assays, which contrasts
with the excellent agreement obtained when used for the
quantitation of the cell culture effects of resveratrol, suggests
that the direct, in vitro inhibitory action of resveratrol on
tyrosinase is influenced by the nature and/or concentration of
substrate. For example, it is possible that resveratrol may
compete more efficiently for L-DOPA binding to tyrosinase in
the tritium release assay, where L-DOPA is present at a low
concentration as a cofactor, rather than in the DOPA oxidase
assay where it is present at a high concentration as a
substrate. Inhibition of tyrosinase activity in NHM by
resveratrol therefore has two components, a direct inhibition
of enzyme activity that is expected to be maximal in the early
stages of treatment, and a temporal-dependent, indirect
downregulation of enzyme activity.
It is well established that treatment of cultured NHM with
cAMP elevating agents can increase tyrosinase activity and
subsequent melanin synthesis (Hunt et al., 1994a, b; Abdel-
Malek et al., 1995; Im et al., 1998). In concert with these
reports, we found that forskolin treatment of cultured NHM
increased their tyrosinase activity (Figure 1d). Combined
treatment with resveratrol and forskolin, however, resulted in
a decrease in tyrosinase activity similar to that seen with
resveratrol alone, whether measured from extracts of treated
cells (Figure 1d) or in situ (data not shown). The mechanism
underlying resveratrol-mediated inhibition of melanin synth-
esis was therefore anticipated to be equally evident in cells
co-treated with forskolin.
Melanogenesis is normally coupled with increased mela-
nocyte dendricity (Busca and Ballotti, 2000) and is exempli-
fied by the ability of forskolin to increase the dendricity of
NHM (Figure 1e). Quantitation of melanocyte dendricity for
Figure 1e revealed that the effect of forskolin was mainly
apparent as an increased number of primary dendrites (2.54
per cell) compared with the control average (2.03 per cell).
Secondary dendritic branching was also promoted by
forskolin exposure, with the proportion of melanocytes
having at least one branching dendrite increased from 3 to
21%. Resveratrol has been reported to promote apoptosis of
www.jidonline.org 2217
RA Newton et al.
Post-Transcriptional Regulation of Tyrosinase
human melanoma cells (Niles et al., 2003); however, survival
of primary melanocytes was not compromised by resveratrol
and surprisingly, treatment with resveratrol resulted in a
positive effect on melanocyte dendricity that was mainly
evident as an enhancement of dendrite length (Figure 1e).
Thus, the total dendrite length per cell was 1.7-fold higher
than in control cells despite a similar number of primary
dendrites (2.1 per cell). Further, 24-hour treatment with the
melanogenesis inhibiting combination of forskolin plus
resveratrol elicited a synergistic increase in dendricity (Figure
1e). In particular, the percentage of melanocytes showing
secondary dendritic branching (63%) was markedly higher
than that seen with either forskolin (21%) or resveratrol (15%)
alone, and contributed to the dramatic increase in total
dendrite length following combination treatment (2.5-fold
greater than control). Therefore, resveratrol has the unusual
property of being both a positive regulator of melanocyte
dendricity and a negative regulator of melanogenesis.
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Figure 1. Resveratrol and cAMP have opposing effects on tyrosinase activity in NHM. (a) In situ tyrosinase activity determined by incubation of cells in
L-DOPA, following 24 hours treatment with either vehicle (Ctrl) or 20 mg/ml resveratrol (Rsvl). Images were captured under identical conditions using bright
field microscopy. Bar¼ 40 mm. (b) Time courses for tyrosinase activity measured by both L-DOPA oxidation and tritium release from [3H]tyrosine using lysates
obtained from NHM treated for the indicated periods of time with resveratrol. Error bars indicate the average7range of two melanocyte strains. (c) The direct
effect of resveratrol on tyrosinase activity was determined by adding resveratrol directly to NHM lysates at an equivalent concentration to that added to cell
cultures. Both the L-DOPA oxidation and tritium release assays were used to quantitate the effect. Error bars represent the mean7SEM of three independent
experiments. (d) Tyrosinase activity of NHM lysates following treatment of NHM with resveratrol alone, forskolin (Fsk) alone (10 mM), or both agents. Values are
given as the mean7SEM (n¼4) of four different melanocyte strains, normalized for total soluble protein and expressed relative to the activity of vehicle-treated
cells, as detailed in materials and methods. (e) Changes in dendritic morphology following the same treatment regime described in (d) were assessed by phase-
contrast microscopy, with dendrite length quantified using ImageJ software. Bar¼ 40 mm. All of the above results are representative of at least two independent
experiments using at least two melanocyte strains.
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MITF levels are increased by forskolin but are unaltered by
resveratrol
To ascertain whether decreased MITF expression could
underlie the depigmentation effects of resveratrol, the levels
of MITF mRNA and protein were determined over the time
frame that inhibition of tyrosinase activity occurred (Figure 2).
In addition, the phosphorylation status of cAMP-responsive
element-binding protein (CREB) and extracellular-regulated
kinase (ERK) were also measured (Figure 2a) because these
activated forms can modulate the levels of MITF in
melanocytes via increased transcription or decreased stabi-
lity, respectively (Vance and Goding, 2004). Forskolin
treatment of NHM induced a rapid increase in phosphory-
lated CREB that was temporally associated with increased
transcription of MITF (Figure 2b), in agreement with the
prevailing concept that activated CREB confers cAMP
responsiveness to the MITF promoter (Price et al., 1998;
Busca and Ballotti, 2000). This increase in RNA was reflected
in a corresponding increase in MITF protein, evident as a
doublet with the higher molecular weight band correspond-
ing to an ERK phosphorylated form (Hemesath et al., 1998).
Treatment of NHM with resveratrol resulted in only a 25%
decrease in MITF transcript levels by 24 hours (Figure 2b), but
with no discernable affect on protein abundance (Figure 2a)
and importantly did not reduce the elevated MITF levels
elicited by forskolin. Furthermore, there was no apparent
effect of resveratrol on the ERK-mediated phosphorylation
status of MITF that could potentially alter stability and/or
DNA binding. This indicated that reduced MITF function
does not explain the inhibition of tyrosinase activity by
resveratrol.
Tyrosinase protein, but not mRNA, is differentially regulated by
forskolin and resveratrol
As MITF is widely regarded as the key regulator of tyrosinase
transcription, we determined the extent to which the levels of
MITF following forskolin and/or resveratrol treatment were
reflected in changes in the steady-state expression of
tyrosinase mRNA (Figure 3a). Resveratrol did not significantly
alter tyrosinase transcript levels in NHM at any of the time
points examined, in agreement with the lack of effect of this
agent on MITF expression (Figure 2a). Interestingly, there was
no significant alteration in tyrosinase RNA expression
following either the forskolin or forskolin plus resveratrol
treatment regimes (Figure 3a), despite the fact that MITF
expression is increased up to 3.5-fold in the presence of
forskolin (Figure 2b). Tyrosinase protein was then examined
to see if post-transcriptional changes could potentially
account for the observed alterations in tyrosinase activity.
Western analysis revealed that human tyrosinase appeared
mostly as an B80 kDa species (Figure 3b), the size of the
mature, fully Golgi-processed form (Halaban et al., 1997).
Exposure of NHM to resveratrol led to a time-dependent
decrease in abundance of mature tyrosinase and, crucially,
this was also seen following co-treatment with forskolin
(Figure 3b, c). Therefore, a post-transcriptionally mediated
decrease in mature tyrosinase protein can account for
resveratrol-elicited reductions in tyrosinase activity. Forskolin
treatment alone markedly increased the level of mature
tyrosinase after 24 hours indicating that a post-translation
regulatory mechanism could potentially explain the elevation
in tyrosinase activity produced by this agent. However, the
extent of this increase in fully processed tyrosinase only
seemed to be partially reflected as elevated tyrosinase activity
(Figure 1c). This may reflect the fact that alterations in the
catalytic activity of tyrosinase cannot be explained simply by
changes in tyrosinase abundance (Iozumi et al., 1993)
because mechanisms regulating the activity of tyrosinase
within the melanosome, the site of melanin synthesis, are also
crucial (Fuller et al., 2001).
Retention of immature tyrosinase in the endoplasmic reticulum
by resveratrol
Examination of the relative abundance of the different forms
of tyrosinase detected by Western analysis indicated potential
effects of resveratrol on the trafficking of tyrosinase. Thus, in
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Figure 2. Effects of forskolin and resveratrol on MITF levels in NHM.
(a) Western-blot analysis of whole-cell lysates prepared from NHM treated for
the indicated times with resveratrol alone, forskolin alone, or both agents.
Phospho-specific antibodies were used to detect phosphorylated CREB and
ERK (p44/p42 MAPK) because these activated forms are involved in the
transcriptional upregulation and phosphorylation of MITF, respectively. The
monoclonal MITF antibody identified the protein as a doublet, with the upper
band previously shown to correspond to MITF that has undergone MAPK
phosphorylation (Hemesath et al., 1998). Similar protein levels were verified
using a phosphorylation-independent ERK antibody. (b) Q-RT-PCR analysis of
MITF RNA levels following the same treatment regime applied for protein
analysis. Transcript abundance was normalized against 18S ribosomal RNA
and expressed relative to the 3 hours control. Each experiment utilized two
melanocyte strains and are presented as the mean7SEM (n¼ 4) of two
independent experiments.
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addition to the dramatic reduction in fully processed 80 kDa
species, evident at 12 and 24 hours following resveratrol,
there also appeared to be a small increase in intensity for a
broad band detected at approximately 70 kDa at these time
points (Figure 3b). This species has previously been shown to
correspond to an immature, endoglycosidase H (Endo H)-
sensitive glycoform of tyrosinase (Halaban et al., 1997) and
indicated that resveratrol may cause aberrant processing of
tyrosinase. Furthermore, it was also apparent that both 12-
and 24-hours treatment with resveratrol resulted in the loss of
a tyrosinase immunoreactive band at around 60 kDa (Figure
3b), a size expected for the deglycosylated, core polypeptide.
The treatment of NHM with proteasomal inhibitors has
previously been shown to induce the accumulation 60 kDa
tyrosinase protein, indicating that a portion of recently
synthesized tyrosinase is targeted for proteolytic degradation
(Halaban et al., 1997). The loss of a similarly sized tyrosinase
species following resveratrol treatment may therefore repre-
sent accelerated transfer of newly synthesized tyrosinase to
the proteasomal complex. The 60 kDa band was not seen in
the control extracts of Figure 4, which may be a consequence
of the lower protein concentration present in these lysates.
Glycosidase digestion was utilized to further evaluate
aberrant trafficking of tyrosinase following treatment with
resveratrol. Digestion with Endo H cleaves oligosaccharides
added in the endoplasmic reticulum (ER) but not those
matured in the Golgi, whereas peptide: N-Glycosidase F
(PNGase F) cleaves both immature and mature oligosacchar-
ides. Inspection of Figure 4 reveals that the majority of
tyrosinase protein extracted from resveratrol-treated NHM
was Endo H-sensitive and hence was ER-retained protein.
This reflects the relative proportions of the 70 and 80 kDa
forms that correspond to Endo H-sensitive and -resistant
populations, respectively. In contrast, tyrosinase from NHM
treated with either vehicle of forskolin alone had mainly the
Golgi processed, Endo H-resistant form, consistent with the
high proportion of mature tyrosinase detected by Western
analysis. Digestion with PNGase F generated a 60 kDa band
representing deglycosylated tyrosinase and demonstrated that
the total amount of tyrosinase was increased by forskolin
whereas it appeared to be reduced by resveratrol (Figure 4).
DCT protein is also differentially regulated by forskolin and
resveratrol
Although changes in the abundance of tyrosinase can
account for the observed changes in tyrosinase activity seen
with these agents, it was also necessary to evaluate whether
there were also alterations in the two TYRPs, TYRP1 and
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Figure 3. Effects of forskolin and resveratrol on tyrosinase levels in NHM.
(a) Q-RT-PCR analysis of tyrosinase RNA levels following treatment of NHM
with resveratrol alone, forskolin alone, or both agents, for the indicated times.
Error bars indicate the mean7SEM (n¼ 4), relative to the 3 hours control,
and were obtained from two melanocyte strains from two independent
experiments. (b) Western-blot analysis of tyrosinase protein levels in whole-
cell lysates prepared from NHM treated as described above. Similar protein
levels were verified using an antibody against GAPDH. Samples were run on
two gels (indicated by gap) and blots processed in parallel under identical
conditions. Vertical lines indicate that single lanes either side of the forskolin
lanes were removed during preparation of the Figure. (c) Fully processed
tyrosinase, represented by the uppermost band at approximately 80 kDa, was
quantified by densitometry of Western-blot autoradiographs. Error bars
indicate the mean7SEM (n¼ 4), relative to the untreated controls, and were
obtained using three melanocyte strains from two independent experiments.
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Arrows at approximately 80 and 60 kDa indicate bands corresponding to the
mature and PNGase F digested forms of tyrosinase, respectively. An Endo
H-sensitive band is coincident with the 70 kDa marker. Samples were run on
two gels (indicated by gap) and blots processed in parallel under identical
conditions. Vertical lines indicate removal of two intervening lanes. Identical
results were obtained in a second independent experiment.
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DCT. These two enzymes are important for the stimulation of
eumelanin production, which is likely to be either due to a
direct catalytic role and/or an ability to stabilize tyrosinase
activity (for review, see Slominski et al., 2004). As was seen
for tyrosinase, the transcript levels for both DCT (Figure 5a)
and TYRP1 (Figure 5c) showed little correspondence with
changes in MITF expression (Figure 2), again implicating the
involvement of additional regulatory factors and/or post-
transcriptional control.
DCT showed extensive differential regulation following
resveratrol and/or forskolin treatment (Figure 5a, b). This was
particularly apparent at the protein level, 12 and 24 hours
after treatment, with forskolin stimulating a profound increase
in DCT, and resveratrol markedly decreasing protein abun-
dance (Figure 5b). Whereas the decrease in DCT protein
could at least partially be accounted for by reduced levels of
mRNA, altered transcription did not seem to be a potential
explanation for the forskolin-stimulated increase in protein
expression. This again suggested that post-transcriptional
regulation might be a crucial mediator of cAMP-induced
increases in melanogenic enzymes.
Analysis of TYRP1 mRNA levels in NHM revealed that
resveratrol treatment caused an approximate 50% decrease in
transcript abundance after 24 hours; however, only a 25%
reduction was seen when forskolin was also present (Figure
5c). Treatment with forskolin alone resulted in a small
increase in TYRP1 mRNA at 12 and 24 hours that approached
25% above control levels. These changes in RNA expression
were reflected by the modest increase in the protein level at
24 hours, as determined by Western analysis (Figure 5d).
Protein levels of the melanosomal protein MART-1 were also
examined in two melanocyte strains following the same
treatment regime and were not altered by resveratrol (data not
shown) providing further evidence that the effects of
resveratrol were not due to a generalized effect on
melanosomal protein stability.
siRNA-mediated knockdown of MITF demonstrates that MITF
expression is required for the maintenance of melanogenic
enzyme transcription
The preceding data indicated that elevation of MITF
expression does not necessarily directly regulate melano-
genic enzyme levels in cultured NHM. However, MITF may
still make an important contribution to the maintenance of
melanogenic enzyme transcription. We therefore utilized a
siRNA against MITF to evaluate the requirement of this
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Figure 5. DCT, TYRP1, SLC45A2, OCA2, and SLC24A5 expression in NHM following treatment with resveratrol, forskolin, or both agents, for the indicated
times. Q-RT-PCR and Western immunoblot analysis was used to determine the levels of mRNA and protein, respectively, for DCT (a, b) and TYRP1 (c, d).
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respectively. Transcript abundance was normalized against 18S ribosomal RNA and expressed relative to the 3 hours control. Error bars indicate the
mean7SEM (n¼ 4) of two independent experiments, each utilizing two melanocyte strains.
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transcription factor for the expression of tyrosinase and
TYRP1 in NHM. The effectiveness of the MITF siRNA in NHM
was shown by MITF mRNA levels being dramatically reduced
to 25% of control levels (Figure 6a), concomitant with a
substantial decrease in MITF protein (Figure 6b). Tyrosinase
and TYRP1 mRNA expression levels in NHM following
siRNA-mediated knockdown of MITF was reduced to
approximately 50 and 40% of that seen in negative controls,
respectively (Figure 6a). Similarly, mRNA levels for SLC24A5,
SLC45A2, and OCA2 were also decreased in NHM trans-
fected with siRNA molecules targeting MITF (data not
shown). These decreases were substantially greater than that
seen for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA (Figure 6a).
Tyrosinase and TYRP1 mRNA expression level changes
were at least partially replicated at the protein level (Figure
6b, c), with TYRP1 protein obviously decreased. For
tyrosinase, the decrease in protein appeared to be mainly
confined to the lower molecular weight bands (Figure 6b),
with decreased protein levels only readily apparent following
PNGase F-mediated digestion to the deglycosylated core
tyrosinase polypeptide (Figure 6c). However, little difference
in tyrosinase activity was detected using the DOPA oxidation
assay (Figure 6d), consistent with this catalytic measure
reflecting changes in the fully processed form of tyrosinase
that showed only minor variation (Figure 6b). Therefore,
some level of MITF expression appears to be required for the
maintenance of melanogenic enzyme transcription in NHM.
DISCUSSION
A number of chemical agents can lead to depigmentation of
human skin, an effect that is commonly due to phenol-based
structures causing direct inhibition of tyrosinase enzymatic
activity (Ando et al., 2007; Solano et al., 2006). An
additional, indirect depigmenting mechanism invokes a key
regulatory role for MITF in governing levels of tyrosinase,
with compounds such as sphingosine-1-phosphate and
sphingosylphosphorylcholine shown to decrease tyrosinase
abundance via a preceding reduction in MITF (Kim et al.,
2003; Kim et al., 2006). Such a mechanism was also
proposed to underlie the inhibition of melanogenesis by
resveratrol (Lin et al., 2002). This suggestion was largely
based on the findings that resveratrol was able to decrease the
activity of an MITF promoter-luciferase reporter construct and
reduce endogenous MITF mRNA levels in NHM. We also
found that resveratrol treatment was able to decrease MITF
mRNA in NHM, however, this reduction was only by 25%
and was not accompanied by any alteration in MITF protein
abundance or tyrosinase transcription. Furthermore, we
found that resveratrol, in the presence of forskolin, actually
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Figure 6. Effect of MITF inhibition on melanogenic enzyme levels in NHM. The cells were transfected with siRNAs that were either directed against MITF
or consisted of a commercial negative control sequence. 48 hours later, cells were assessed for expression of MITF, tyrosinase, TYRP1, and GAPDH by
(a) Q-RT-PCR measurement of mRNA, and (b) Western-blot analysis of protein. (c) Cellular lysates containing tyrosinase were also prepared from identically
treated cells then digested with PNGase F to facilitate comparison of core deglycosylated tyrosinase protein levels by Western analysis. (d) Cellular lysates were
also assessed for relative tyrosinase activity using the DOPA oxidation assay. Error bars represent the mean7SEM (n¼ 3) of three independent experiments.
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elevated levels of MITF mRNA and protein, despite the fact
that the inhibition of tyrosinase activity by this treatment
combination is virtually identical to that seen with resveratrol
alone. Therefore downregulation of endogenous MITF
expression did not account for resveratrol-mediated depig-
mentation and a new mechanistic explanation was required.
Our data demonstrated that at least two mechanisms
underlie the inhibition of tyrosinase activity following
resveratrol treatment of NHM. The first mechanism caused
a reduction of tyrosinase protein levels that was shown to
correlate with the major decrease in tyrosinase activity seen
after 18–24 hours. Secondly, resveratrol had the capacity to
directly inhibit tyrosinase activity when added to cell
extracts, an effect that has been previously described (Kim
et al., 2002b). Although the decrease in tyrosinase protein
can account for the time-dependent reduction in tyrosinase
activity measured in lysates from treated NHM, it is unclear
to what extent the direct inhibition mechanism contributes to
reduced tyrosinase activity in situ. The influence of direct
inhibition, however, would be expected to decline with time
because studies on resveratrol uptake in cultured human
hepatic cells demonstrated that intracellular levels peak
within 10 minutes then gradually decrease (Lancon et al.,
2004). The high-affinity interaction between resveratrol and
tyrosinase revealed by the in vitro studies may also be
relevant for the molecular mechanism mediating long-term
downregulation of tyrosinase protein.
Resveratrol treatment of NHM substantially decreased the
amount of tyrosinase protein without affecting steady-state
levels of tyrosinase RNA confirming that regulation of
tyrosinase transcription does not mediate depigmentation
by resveratrol. The basis for the decrease in tyrosinase protein
was revealed by Western analysis and glycosidase digestion,
with extracts from resveratrol treated NHM shown to consist
mostly of ER-retained, immature tyrosinase, whereas control
NHM contained mainly the mature, Golgi-processed form.
Therefore resveratrol treatment disrupted the trafficking of
tyrosinase from the ER to the Golgi leading to a dramatic
decrease of functional tyrosinase. Interestingly, retention of
tyrosinase in the ER can also occur for mutant forms of
tyrosinase that cause type I oculocutaneous albinism
(Halaban et al., 2000). Furthermore, the loss of pigmentation
that is often seen in human melanomas has also been shown
to be the result of aberrant ER retention, with tyrosinase again
mainly evident as a 70 kDa Endo H-sensitive, immature form
(Halaban et al., 1997). This ER-trapped form is also subject to
increased proteolytic degradation (Watabe et al., 2004)
accounting for the overall decrease in tyrosinase protein
evident following resveratrol exposure.
Depigmentation due to ER-retained tyrosinase has recently
also been demonstrated in melanoma cells that have been
engineered to display enhanced sensitivity to oxidative stress
via downregulation of the L-ferritin gene (Maresca et al.,
2006). Resveratrol, however, is a free radical scavenger and
thus would be expected to decrease oxidative stress. This
suggests that the antioxidant properties of resveratrol are
unlikely to account for its effects on tyrosinase maturation.
Intriguingly, there also appears to be another polyphenol
compound with considerable structural similarity to resver-
atrol, 2,20-dihydroxy-5,50-dipropyl-biphenyl, that appears to
downregulate melanogenesis in mouse B16 melanoma cells
in a similar manner (Nakamura et al., 2003). Thus, 2,20-
dihydroxy-5,50-dipropyl-biphenyl treatment for 24 hours
strongly suppressed tyrosinase activity, an effect that was
also explained via ER-retention of tyrosinase and a subse-
quent acceleration of tyrosinase degradation (Nakamura
et al., 2003). Although 2,20-dihydroxy-5,50-dipropyl-biphenyl
did not show any direct inhibition of tyrosinase, it may share
with resveratrol a structural ability to interact with tyrosinase
to hinder correct folding/processing of the protein. Misfolding
of mutant tyrosinase from albino melanocytes underlies the
subsequent increase in ER retention and degradation of
tyrosinase (Halaban et al., 2000). The importance of folding
in tyrosinase maturation has also been demonstrated in
amelanotic melanomas by the ability of the tyrosinase
substrates, DOPA and tyrosine, to facilitate the correct
folding of the enzyme to the mature, proteolytically resistant
form (Halaban et al., 2001). Also crucial for tyrosinase
trafficking is the pH within the ER-Golgi compartments, with
amelanotic melanoma cells shown to have enhanced
tyrosinase maturation and to pigment following treatment
with agents that increase the luminal pH of subcellular
organelles (Halaban et al., 2002). In this regard, it of interest
that resveratrol was able to decrease expression of two genes,
SLC45A2 and SLC24A5, which encode transmembrane
proteins implicated in the regulation of ion transport (for
review, see Sturm, 2006). Therefore, resveratrol, either
directly or indirectly, may alter the processing environment
with concomitant ER retention of tyrosinase.
In contrast to tyrosinase, the profound decrease in DCT
protein elicited by resveratrol was also accompanied by a
corresponding reduction in mRNA, implicating transcription
control. The decrease in DCT following resveratrol treatment
could contribute to skin depigmentation and may also have
relevance for potential chemotherapeutic applications.
Although we did not observe an effect of resveratrol on the
proliferation of primary melanocytes, it has been shown to
induce apoptosis in melanoma cells (Niles et al., 2003) and
increase sensitivity to anticancer therapy (Fulda and Debatin,
2004; Yang et al., 2005). The chemotherapy sensitization
effects towards melanoma may relate, in part, to decreased
DCT levels, because expression of DCT has been associated
with resistance to chemo- and radiotherapy (Chu et al., 2000;
Pak et al., 2004).
Stimulation of pigmentation following activation of the
cAMP signal transduction cascade is at least partially
attributable to an upregulation of melanogenic enzymes
and studies with gene reporter assays have implicated a key
role for MITF in such induction via transcriptional control of
melanogenic genes (Bertolotto et al., 1998a, b; Price et al.,
1998; Busca and Ballotti, 2000). However, the forskolin-
elicited upregulation of tyrosinase and DCT proteins in NHM
described in this study was not associated with an increase in
tyrosinase or DCT transcription, despite a robust increase in
MITF expression. Previous evidence for post-transcriptional
control of melanogenic enzyme levels in NHM was provided
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in a report where a-MSH stimulated an increase in tyrosinase,
TYRP1, and DCT protein without altering respective mRNA
levels, as detected by Northern analysis (Abdel-Malek et al.,
1995). The inability of elevated MITF protein to stimulate
tyrosinase and DCT transcription in this investigation may be
a consequence of the endogenous context of the tyrosinase
promoter, a concept supported by a study using adenovirus
encoding wild-type MITF which demonstrated that exogen-
ous MITF was not sufficient to increase levels of endogenous
tyrosinase and TYRP1 protein in NHM (Gaggioli et al., 2003).
This latter study also utilized adenovirus expressing dominant
negative MITF to demonstrate that MITF was, however, still
required for maintaining endogenous tyrosinase gene expres-
sion. Our study employed siRNA-mediated knockdown of
MITF to similarly examine the relationship between MITF and
constitutive enzyme levels, and we also observed a sig-
nificant decrease in tyrosinase and TYRP1 expression in
NHM following a 75% reduction in MITF mRNA levels. Our
data therefore support the concept that ‘MITF is required, but
is not sufficient to induce the expression of melanogenic
genes’ (Gaggioli et al., 2003).
An alternative mechanistic basis for the observed post-
transcriptional upregulation of melanogenic proteins by
cAMP is therefore required. Insight into the molecular
scheme responsible for the increase may be provided by
the observation that the two melanogenic proteins with well-
characterized enzyme activity, tyrosinase, and DCT, were
strongly increased by forskolin, in contrast to TYRP1, a
protein that may not have an enzymatic role (Boissy et al.,
1998). An attractive possible mechanism is that the cAMP
signaling pathway can influence the enzyme environment to
modulate activity and subsequent processing and/or traffick-
ing. We therefore investigated this possibility by quantitating
the expression of the genes SLC45A2, OCA2, and SLC24A5
that encode transmembrane proteins implicated in the
regulation of ion transport and/or the processing and
trafficking of melanogenic enzymes (Sturm, 2006). The most
dramatic effect of forskolin was a twofold increase in
expression of the SLC45A2 gene, encoding the MATP protein,
which is likely to reflect the ability of SLC45A2 to be
transcriptionally modulated by MITF (Du and Fisher, 2002),
(our data, not shown). As MATP plays a crucial role in
tyrosinase trafficking and stability (Costin et al., 2003), the
upregulation of this protein provides a promising candidate to
facilitate the increased tyrosinase abundance. However, it is
difficult to reconcile the greater upregulation of DCT than
TYRP1 by such a MATP-mediated mechanism because DCT
trafficking is the least affected melanogenic enzyme in mice
with defective MATP function (Costin et al., 2003). Forskolin
also induced a 1.5-fold increase in expression of the OCA2
gene encoding the P-protein. The P-protein has been shown
to be crucial for normal post-translational processing and
trafficking of tyrosinase in the ER (Chen et al., 2002).
However, it has also been reported that melanocytes cultured
from p-null mice can still elevate tyrosinase levels in response
to IBMX, a cAMP phosphodiesterase inhibitor, although it
was not established whether this was a transcriptional or
post-translational effect (Chen et al., 2004).
Post-transcriptional regulation of melanogenic enzyme
expression has previously been primarily associated with the
inhibition of melanin synthesis, as evident in amelanotic
melanoma and classic oculocutaneous albinism. The loss of
tyrosinase activity and ER retention of misfolded tyrosinase
that underlies such loss of pigmentation has now also been
shown to be the main mechanism responsible for the
profound loss of pigmentation elicited by the chemopreven-
tative agent resveratrol. Our data also indicated that post-
transcriptional upregulation of melanogenic enzyme levels
represents an important regulatory control point for melanin
synthesis following activation of the cAMP pathway in NHM.
As upregulation of tyrosinase and DCT is an important
component of the photoprotective delayed tanning response,
further understanding of the molecular details of this post-
transcriptional control may have significant therapeutic
implications.
MATERIALS AND METHODS
Materials
Antibodies against the following human proteins were used:
tyrosinase (monoclonal T311, Upstate, Charlottesville, VA), DCT
(TRP2, D-18, Santa Cruz Biotechnology, Santa Cruz, CA), TYRP1
(monoclonal B8G3 (Takahashi and Parsons, 1990), a gift from P.
Parsons), MITF (Ab-2, monoclonal D5) and MART-1 (NeoMarkers,
Melbourne, Australia), phospho-CREB (Upstate), phospho-ERK
(phospho-p44/42 MAPK, monoclonal E10, Cell Signaling Technol-
ogy, Beverly, MA), ERK (p44/42 MAPK, Cell Signaling Technology),
and GAPDH (Genzyme, Cambridge, MA). Horseradish peroxidase-
conjugated secondary antibodies against rabbit or mouse IgG were
purchased from Upstate. The horseradish peroxidase-conjugated
anti-goat secondary antibody, forskolin, resveratrol, and activated
charcoal were all obtained from Sigma-Aldrich (Sydney, NSW,
Australia). L-Tyrosine-3,5-3H (33.9 Ci/mmol) was purchased from
Perkin Elmer (Melbourne, VIC, Australia).
Cell culture
Queensland foreskin primary melanocyte strains were isolated and
propagated from anonymous neonatal foreskin samples as described
previously (Leonard et al., 2003) and maintained in RPMI-1640
media containing 3 mM HEPES buffer supplemented with 8% heat-
inactivated fetal bovine serum, penicillin/streptomycin (40 mg/ml),
1 mM pyruvic acid, 0.2 mM. nicotinamide, 10 ng/ml TPA, 5 ng/ml
bFGF, and 0.6 mg/ml cholera toxin. One week before, and for the
duration of, experimentation, cholera toxin was removed from the
melanocyte growth media to facilitate investigation of cAMP-
mediated responses. Stimulation of NHM was carried out in culture
media that had been present for 3 days since seeding. The
melanocyte strains used were all from Caucasian donors with a
darkly pigmented and lightly pigmented strain used for all
experiments. A further melanocyte strain of intermediate pigmenta-
tion was also used for tyrosinase, DCT, and TYRP1 Western
immunoblot analysis. The study was conducted according to the
Declaration of Helsinki Principles, and ascertainment of foreskin
tissue samples was approved by the University of Queensland
Medical Research Ethics Committee and QIMR Human Research
Ethics Committee. Experiments were conducted with parental
consent to the use of tissue for research.
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Tyrosinase activity assays and L-DOPA staining
To prepare cell extracts following drug treatment, cells were washed
in ice-cold phosphate-buffered saline (PBS), lysed in 0.1 M
phosphate buffer (pH 6.8) containing 1% Triton X-100 and complete
protease inhibitor cocktail (Roche Diagnostics, Sydney, NSW,
Australia) for 20 minutes at 41C, then clarified by centrifugation
(13,000 g, 5 minutes). The tyrosinase activity of 100ml aliquots of
extract was then determined by either measuring the rate of
oxidation of L-DOPA (Takahashi and Parsons, 1992) or the release
of tritium from tyrosine-3,5-3H (Pomerantz, 1966). For the DOPA
oxidation assay, 100 ml duplicates were incubated with 100 ml
L-DOPA (3 mg/ml in 0.1 M phosphate buffer, pH 6.8) at 371C. The
absorbance at 490 nm was measured every 30 minutes for at least
2 hours and the tyrosinase activity calculated as OD490/min/mg of
lysate protein then expressed relative to the activity of vehicle-
treated cells. To assess direct inhibitory effects on tyrosinase activity,
compounds were added to cell lysates at an equivalent concentra-
tion to that used for treating whole-cell cultures, incubated for
5 minutes at room temperature, mixed with L-DOPA solution and
incubated for 2 hours at 371C, as described above. The protein
concentration of extracts was determined by a BCA assay (Pierce,
Rockford, IL, USA). The tritium release assay of Pomerantz
(Pomerantz, 1966) was performed essentially as first described.
Briefly, 100ml of cell extract was added to a 900 ml reaction mixture
containing 0.1 M phosphate buffer (pH 6.8) and 0.1 mM phenyl-
methanesulfonylfluoride. For experiments examining the in vitro
effects of resveratrol, the drug or DMSO was also added at this stage
to give the desired final concentration and incubated at room
temperature for 5 minutes. L-DOPA (0.03 mM final concentration)
and 1mCi tyrosine-3,5-3H were then added and the reaction
incubated for 1 hour at 371C. The reaction was stopped by adding
50 ml 1 M HCl then mixed with approximately 100 mg activated
charcoal for 1 hour at room temperature, centrifuged briefly and
200ml supernatant mixed with 1.8 ml scintillation fluid, and
counted. Background counts were assessed using 100 ml 0.1 M
phosphate buffer in place of cell extract.
In situ L-DOPA reactivity of NHM was assessed using cultures
fixed with 4% paraformaldehyde in PBS for 40 min at room
temperature. Following permeabilization in 0.1% triton X-100 in
PBS for 2 min, cells were washed with PBS and incubated in 0.1%
L-DOPA for 3 hours at 371C. Cells were then rinsed in PBS and
images captured using an Olympus CKX41 inverted microscope
equipped with an Olympus Camedia C-5060 digital camera.
siRNA transfection
A predesigned siRNA directed against MITF (Ambion, Austin, TX, ID
No. 115142) was used to downregulate MITF, and a commercial
negative control sequence (Ambion, Catalogue No. 4611) was used
to monitor for off-target effects. NHMs were seeded in complete
growth medium in 10 cm dishes (5 105 cells) or 6-well plates
(2 105 cells per well) and allowed to adhere for 48 hours.
Transfection of siRNAs was carried out essentially as described
previously (Cook et al., 2005). Briefly, siRNA molecules were
transfected at a concentration of 100 pmol using 5 ml Lipofectamine
2000 (Invitrogen, Melbourne, VIC, Australia) per 1 ml consisting of
50% OptiMEM and 50% growth medium without antibiotics. After
6 hours, an equal volume of growth medium lacking antibiotics was
added and the cells cultured overnight. Twenty-four hours post-
transfection, the liposomes were aspirated and the medium replaced
with growth medium lacking antibiotics and the culture continued
for a further 24 hours before preparation of total protein lysates,
DOPA oxidation assay extracts, or total RNA extracts as appropriate.
Gene expression quantitation
RNA extraction, DNase treatment and quantitative real-time poly-
merase chain reaction (Q-RT-PCR) procedures were carried out
essentially as previously described (Newton et al., 2005; Roberts
et al., 2006). Ten percent of cDNA synthesis reactions from 0.3mg
total RNA were used in 25 ml Q-RT-PCR reactions containing
TaqMan gene expression assays (Applied Biosystems, Foster
City, CA, USA) for either tyrosinase (Hs00165976_m1), DCT
(Hs00157244_m1), TYRP1 (Hs00167051_m1), MITF (Hs00165
156_m1), GAPDH (Hs99999905_m1), OCA2 (Hs00609341_m1),
SLC45A2 (Hs00211813_m1), or SLC24A5 (Hs01385408_m1),
together with TaqMan PCR master mix. Transcript levels were
normalized against 18S ribosomal RNA that was quantified using
a Pre-Developed TaqMan assay for 18S (Applied Biosystems) and
50-fold diluted cDNA. Q-RT-PCR was performed in 96-well plates
on an ABI Prism 7500 Sequence Detector system using a two-step
thermal cycling protocol of 40 cycles of 951C for 15 s and 601C for
1 minute.
Western immunoblot analysis
Following appropriate periods of treatment at 371C, culture plates
were placed on ice, rinsed with ice-cold PBS, SDS extraction buffer
added and Western blotting performed as described previously
(Newton et al., 2005). PageRuler prestained protein standards
(MBI Fermentas, Quantum Scientific, Brisbane, QLD, Australia) were
used for molecular weight estimation. Membranes were blocked in
Tris-buffered saline (TBS) (pH 7.6), 0.05% Tween 20, 5% skim
milk powder for 1 hour at room temperature. Primary antibodies
were used at the following dilutions: anti-tyrosinase, 1:4,000; anti-
DCT, 1:500; anti-TYRP1, 1:20; anti-MITF, 1:1,000; anti-GAPDH,
1:10,000; anti-phospho-CREB, 1:1,000; anti-phospho-ERK, 1:2,000;
anti-ERK, 1:1,000; anti-MART-1, 1:1,000. Dilutions were all in fresh
5% skim milk blocking buffer, apart from ERK where BSA replaced
milk. Incubations were overnight at 41C, except for TYRP1 which
had 1.5 hours at room temperature. After washing in TBS, 0.1%
Tween 20 (3 10 minutes at room temperature), the appropriate
horseradish peroxidase-conjugated secondary antibody was incu-
bated with the blot for 1 hour at room temperature (1:10,000 in 3%
blocking buffer). Following washing, as above, the blot was exposed
to Supersignal West Pico (Pierce) for detection. The relative intensity
of bands was determined by scanning films on a GS800 calibrated
densitometer (Bio-Rad, NSW, Australia), followed by volumetric
quantitation using Quantity One software (Bio-Rad). The signal
obtained from reprobing blots with GAPDH was used to monitor for
equal total protein levels.
Glycosylation analysis
Protein was extracted from NHM using the same lysis buffer
employed for the tyrosinase assay and the protein concentration
determined by the BCA procedure. 10 mg aliquots of lysate were then
digested with 500 U Endo H or PNGase F (New England Biolabs,
Beverly, MA), or incubated with reaction buffer alone, in accordance
to the conditions specified by the manufacturer. After incubation,
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samples were mixed with SDS extraction buffer (5 ), heat
denatured, and detected by Western immunoblotting using anti-
tyrosinase, as described above.
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